Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2008
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:B01AF01
|
| gptkbp:bioavailability |
80-100%
|
| gptkbp:brand |
gptkb:Xarelto
|
| gptkbp:CASNumber |
366789-02-8
|
| gptkbp:contraindication |
active pathological bleeding
severe hypersensitivity to rivaroxaban |
| gptkbp:drugClass |
gptkb:anticoagulant
|
| gptkbp:eliminatedIn |
renal
biliary |
| gptkbp:eliminationHalfLife |
5-9 hours (young), 11-13 hours (elderly)
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasBoxedWarning |
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation |
| gptkbp:hasInChIKey |
MUNRUTXBAQUQKT-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
gptkb:C19H18ClN3O5S
|
| gptkbp:hasSMILES |
CC1=NN(C2=C1C=CC(=C2)Cl)C(=O)C3=CC=C(C=C3)S(=O)(=O)NC(=O)O
|
| gptkbp:hasUNII |
Y6O7T4G8P9
|
| https://www.w3.org/2000/01/rdf-schema#label |
DB06292
|
| gptkbp:indication |
prevention of venous thromboembolism after hip or knee replacement surgery
treatment of deep vein thrombosis treatment of pulmonary embolism prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation |
| gptkbp:legalStatus |
prescription only
patented |
| gptkbp:manufacturer |
gptkb:Bayer
gptkb:Janssen_Pharmaceuticals |
| gptkbp:mechanismOfAction |
direct factor Xa inhibitor
|
| gptkbp:metabolism |
hepatic (CYP3A4, CYP2J2, CYP-independent mechanisms)
|
| gptkbp:molecularWeight |
435.88
|
| gptkbp:name |
gptkb:Rivaroxaban
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
92-95%
|
| gptkbp:PubChem_CID |
gptkb:DB06292
9875401 D08917 68547 8058577 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea bleeding dyspepsia |
| gptkbp:synonym |
gptkb:BAY_59-7939
|
| gptkbp:target |
coagulation factor Xa
|
| gptkbp:bfsParent |
gptkb:dapagliflozin
|
| gptkbp:bfsLayer |
7
|